268 reports of this reaction
1.8% of all CEFTAZIDIME reports
#10 most reported adverse reaction
FEBRILE NEUTROPENIA is the #10 most commonly reported adverse reaction for CEFTAZIDIME, manufactured by Hospira, Inc.. There are 268 FDA adverse event reports linking CEFTAZIDIME to FEBRILE NEUTROPENIA. This represents approximately 1.8% of all 14,861 adverse event reports for this drug.
Patients taking CEFTAZIDIME who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for CEFTAZIDIME, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for CEFTAZIDIME:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 268 FDA reports for CEFTAZIDIME. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 1.8% of all adverse event reports for CEFTAZIDIME, making it a notable side effect.
If you experience febrile neutropenia while taking CEFTAZIDIME, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.